Minoxidil for hair loss: what the controlled trials show

Minoxidil is one of only two drugs the U.S. Food and Drug Administration has cleared for pattern hair loss (androgenetic alopecia), alongside finasteride. It started life as a blood-pressure pill, and the hair growth it caused as a side effect turned it into a topical treatment. This article reports what randomized controlled trials, systematic reviews, and dermatology sources have found about how well it works, how long it takes, and what is known about the newer oral form. It is evidence reporting, not medical advice.

What the topical trials found

The core evidence for topical minoxidil in men comes from large, placebo-controlled trials. In a 48-week study of 393 men, 5% solution produced a bigger increase in hair count than 2% solution, and both beat placebo (Journal of the American Academy of Dermatology, 2002). The average gain was about 18.6 non-vellus hairs per square centimeter with 5%, versus 12.7 with 2%. Those numbers matter for setting expectations: the effect is real and measurable, but it is a partial improvement in density, not a full reversal of balding.

A later trial tested a 5% foam formulation in 352 men over 16 weeks. Target-area hair count rose 13.4% with the foam versus 3.4% with placebo (Journal of the American Academy of Dermatology, 2007). The foam was developed partly to drop propylene glycol from the vehicle, which tends to reduce the itching and irritation some users get from the solution. Head-to-head data on whether foam or solution regrows more hair is limited, so the practical difference between them is mostly about tolerability and ease of use rather than proven superiority of one over the other.

In women, a 48-week randomized trial compared 5% and 2% solutions against placebo for female pattern hair loss (Journal of the American Academy of Dermatology, 2004). Both active concentrations helped, and the 5% version carried more reports of itching, local irritation, and unwanted facial hair (hypertrichosis). For that reason the 2% strength has often been the labeled choice for women, though prescribing patterns vary.

The shedding phase and the timeline

A common surprise in the first weeks is increased shedding. This is a recognized, temporary effect. Minoxidil pushes resting (telogen) follicles to exit early and re-enter the growth (anagen) phase, a process sometimes called immediate telogen release. Because many follicles shift at once, users can see a burst of shedding that typically starts within the first two to eight weeks and settles by around week 12. It reflects the hair cycle resetting rather than the drug failing.

Visible regrowth is slow. Dermatology sources and the trial designs themselves point to roughly 4 to 6 months before density changes become noticeable, which is why studies run for 16 to 48 weeks and why clinicians generally advise judging results at 12 months, not sooner. There is an important catch that the trials make clear: the benefit depends on continued use. Stopping the drug leads to loss of the newly maintained or regrown hair within about 3 to 4 months, returning the scalp toward its untreated pattern.

The major development: low-dose oral minoxidil

The biggest shift in the last few years is the rise of low-dose oral minoxidil (LDOM), used off-label at doses far below the old blood-pressure range, typically 0.25 to 5 mg per day. It is not FDA-approved for hair loss, but prescriptions have climbed because it is a once-daily pill rather than a twice-daily liquid, which many patients find easier to keep up.

The strongest efficacy comparison so far is a 2024 randomized trial in JAMA Dermatology. It assigned 90 men to either oral minoxidil 5 mg daily or topical minoxidil 5%, with 68 completing 24 weeks. Oral minoxidil was well tolerated but did not demonstrate superiority over the topical form. The difference in vertex terminal-hair density favored the oral group by 23.4 hairs per square centimeter, but this did not reach statistical significance (P = .09), and frontal measures showed no meaningful gap (JAMA Dermatology, 2024). The reasonable read is that oral and topical worked similarly in this study, so the appeal of the pill is convenience rather than a clear efficacy edge. Unwanted body hair was more common with the oral form (49% versus about 25%).

What is known about oral minoxidil safety

Safety is the reason clinicians watched this trend carefully, since oral minoxidil at high doses can affect the heart and cause fluid retention. The largest safety dataset is a multicenter review of 1,404 patients (Journal of the American Academy of Dermatology, 2021). The most frequent side effect was hypertrichosis (extra hair on the face or body) at 15.1%, which led only about 0.5% of patients to stop. Systemic effects were uncommon: lightheadedness 1.7%, fluid retention 1.3%, fast heart rate 0.9%, and headache 0.4%. Overall, fewer than 2% discontinued because of systemic effects.

A prospective study added objective heart data. Thirty men on 5 mg daily wore 24-hour Holter monitors and ambulatory blood-pressure monitors at baseline and 24 weeks (Journal of the American Academy of Dermatology, 2022). Blood pressure dipped slightly but not to the point of clinical low blood pressure, and clinically significant cardiac problems were not seen. Separate work suggests higher doses (for example 7.5 mg) can raise heart rate, which is part of why lower doses are favored for hair loss. Reviews summarizing this body of evidence conclude that in appropriately selected, monitored patients, low-dose oral minoxidil has a favorable safety profile, while noting the data are mostly observational rather than large long-term randomized trials (Expert Opinion on Pharmacotherapy, 2024).

Where the evidence stops

Two caveats run through all of it. First, minoxidil in any form partially maintains and regrows hair rather than curing pattern baldness, and average gains in trials are modest. Second, results are use-dependent: whatever a person keeps has to be maintained with ongoing treatment. Where the newer oral option is concerned, the efficacy trials are still small and short, so confidence in long-term benefit and rare risks is lower than for the decades of topical data.

This article reports what published trials, reviews, and regulatory labels describe. It is not medical advice, and decisions about starting, dosing, or stopping any medication (especially an oral drug with cardiovascular effects) should be made with a licensed clinician.

Common questions

Does 5% minoxidil work better than 2%?

In randomized trials of men, 5% topical minoxidil produced a larger increase in hair count than 2% and both beat placebo (Journal of the American Academy of Dermatology, 2002). In women, 5% also worked but carried more irritation and unwanted facial hair, so the 2% strength has often been labeled for female use.

Is minoxidil shedding normal, and how long does it last?

Yes. An early increase in shedding is a documented effect of minoxidil resetting the hair cycle (immediate telogen release). It usually begins within the first two to eight weeks and settles by about week 12. It reflects follicles shifting into a growth phase, not the drug failing.

How long until minoxidil shows visible results?

Density changes generally become noticeable around 4 to 6 months of consistent use, and clinicians typically advise judging results at about 12 months. This is why the trials ran for 16 to 48 weeks.

Is oral minoxidil more effective than the topical form?

A 2024 JAMA Dermatology randomized trial found daily oral minoxidil 5 mg was not superior to 5% topical minoxidil in men after 24 weeks. The two performed similarly, so the main draw of the pill is convenience rather than a proven efficacy advantage. Oral minoxidil is off-label and not FDA-approved for hair loss.

Do you have to keep taking minoxidil forever?

To keep the benefit, yes. Dermatology sources report that stopping minoxidil, oral or topical, leads to loss of the newly maintained hair within about 3 to 4 months as the scalp returns toward its untreated pattern.